[Clinical characteristics and analysis of prognostic factors of 222 patients diagnosed with Hodgkin's lymphoma].

Hu, Y F; Huang, Y H; Luo, W; Chen, M X; Zhang, J; Gou, F

Hu, Y F; Huang, Y H; Luo, W; Chen, M X; Zhang, J; Gou, F.

Afiliación

Hu YF; Department of Oncology, Affiliated Hospital of Guizhou Medical University/Department of Lymphoma, Guizhou Cancer Hospital,Gui Yang 550001,China.
Huang YH; Department of Oncology, Affiliated Hospital of Guizhou Medical University/Department of Lymphoma, Guizhou Cancer Hospital,Gui Yang 550001,China.
Luo W; Department of Oncology, Affiliated Hospital of Guizhou Medical University/Department of Lymphoma, Guizhou Cancer Hospital,Gui Yang 550001,China.
Chen MX; Department of Oncology, Affiliated Hospital of Guizhou Medical University/Department of Lymphoma, Guizhou Cancer Hospital,Gui Yang 550001,China.
Zhang J; Department of Oncology, Affiliated Hospital of Guizhou Medical University/Department of Lymphoma, Guizhou Cancer Hospital,Gui Yang 550001,China.
Gou F; Department of Oncology, Affiliated Hospital of Guizhou Medical University/Department of Lymphoma, Guizhou Cancer Hospital,Gui Yang 550001,China.

Zhonghua Yi Xue Za Zhi ; 99(48): 3792-3796, 2019 Dec 24.

Article en Zh | MEDLINE | ID: mdl-31874516

Asunto(s)

Enfermedad de Hodgkin; Protocolos de Quimioterapia Combinada Antineoplásica; Bleomicina; Dacarbazina; Supervivencia sin Enfermedad; Doxorrubicina; Humanos; Pronóstico; Estudios Retrospectivos; Vinblastina

Palabras clave

Lymphoma; Prognosis; Treatment outcome

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: Zh Revista: Zhonghua Yi Xue Za Zhi Año: 2019 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google